A pioneering new clinical trial involving cannabis in treating dementia has been approved by the Human Research Ethics Committee of the University of Notre Dame in Western Australia. The study is expected to take about 14 months and involve 50 people who are living in a residential aged care facility. It will also study whether the drug can boost appetite in dementia patients. As a natural remedy, cannabis is a promising alternative to pharmaceuticals.
While small-scale studies have provided promising results, large-scale clinical trials will be required to prove the effectiveness of marijuana for this disease. The new study will examine the effect of cannabis on the endocannabinoid system, which is thought to play a critical role in the progression of the disease. Several organizations are preparing for large-scale clinical trials to test the safety and efficacy of cannabis for treating dementia.
The trial will be conducted by King’s College London and the Institute of Psychiatry, Psychology & Neuroscience at the University of Notre Dame. The study will focus on reducing agitation and aggression in patients with dementia. The researchers will also look at the safety of Sativex, a peppermint-flavored mouth spray, which contains both THC and CBD. The study is designed to help doctors decide whether cannabis is a safe and effective treatment for dementia.
As a result of the success of the trials, the FDA has approved a medical cannabis product called CogniCann, which is a specialized medical cannabis extract that has been shown to improve memory and cognitive functions. The pharmaceutical company will supply the UNDA researchers with CogniCann, a specially-formulated strain of cannabis that contains THC and other cannabinoids. The pharmaceutical company has operations in the Czech Rep., Slovenia, and the United Kingdom.
Although the trial on CBD has not been conducted in humans, the findings are promising. The cannabinoid may help reduce symptoms of depression, agitation, and psychosis in patients with dementia. A recent survey showed that cannabis was used by around 20% of MS patients. This could lead to a low-cost, effective medication for those with Alzheimer’s. It is worth mentioning that there are still no strong studies on the effects of cannabis on dementia, but the benefits of a healthy lifestyle and a plant-based diet are positive.
The results from the study indicate that CBD may be an effective alternative medication for dementia. The compounds in the substance have the potential to modify the disease and treat the symptoms of Alzheimer’s disease. It does not cause a high, but it does have neuroprotective effects. Moreover, the researchers do not know whether the drug will last long term. The study will continue to require more research to determine if CBD is beneficial in the long run.
The benefits of cannabis for dementia patients may also extend to the health of caregivers. It is thought that cannabinoid can reduce the number of medications needed by the patients. The study is also helpful for dementia patients in improving their quality of life. It can also reduce the amount of medication required to treat Alzheimer’s disease. This study will be conducted in Perth. It will help to improve the quality of life of those who suffer from the condition.
The findings of the study suggest that the use of cannabis may benefit people with Alzheimer’s disease. It has also been shown to improve memory and reduce the risk of dementia. Despite the negative effects, however, the findings indicate that it is a viable alternative for preventing or treating this disorder. The benefits of cannabis have been widely recognized, and further studies are expected to provide more evidence. The drug also appears to be beneficial for a variety of conditions. In addition to treating Alzheimer’s, it can help those suffering from chronic pain, chemotherapy side effects, and behavioural symptoms.
In the first phase of the trial, participants were given a cannabis extract that contained up to 80% THC. The results also showed positive effects in tremors, rigidity, and bradykinesia. Twenty-eight of the 28 patients the definitive guide to growing marijuana for recreational and medical use were well tolerated. This is a promising development in the field of dementia. It could provide a base for future medical trials. This study will be important for the medical community and the elderly.